Tag:
Rasilez
Latest Headlines
Latest Headlines
Novartis to revamp Rasilez label with safety risks
The data on Rasilez 's safety risks is coming home to roost. The Novartis ( $NVS ) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...
Novartis ends Tekturna trial on safety concerns
Bad news for Novartis' ( $NVS ) blood pressure med Tekturna (aka Rasilez ). The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also
Blockbuster hopes for Rasilez fade at Novartis
Novartis' ( $NVS ) bid to expand the use of Rasilez has run into serious trouble. The pharma company joined the lineup of Big Pharma companies reporting trial setbacks today with the news that
Novartis grabs European approval of combo pill for high blood pressure
Swiss drug giant Novartis ( $NVS ) revealed Monday that it has a green light to market a combo pill in the European Union to patients who need multiple meds to control their high blood pressure. The
Rasilez approval spurs Novartis expansion
Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a €183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost
